Skip to content
value.today

Alpine Immune Sciences, Inc.

ALPN
$1.1 Blast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$30 M
Dec-2022 ending year
value.today research
Net income
$-58 M
-192.3% margin
value.today research
Employees
—

Alpine Immune Sciences, Inc. in brief

Alpine Immune Sciences, Inc. is a listed company in the Biotechnology industry, based in Seattle, Washington, USA. It was founded in 2014. Its last known market value was $1.1 B (January 2024); there is no current figure. In the year to Dec 2022 it had sales of $30 M and a net loss of $58 M. Its shares trade under the symbol ALPN (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

Alpine Immune Sciences, Inc. timeline

3 events, 2015
  1. 2015
  2. 🏁
    · approximate
    Founded
  3. 🔔
    · approximate
    Initial public offering on Nasdaq
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.

Events of Alpine Immune Sciences, Inc. from Wikidata, the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$290 M$581 M$871 M$1.2 B20202021202220232024

World rank over time

▲ up 12,102 places since 2020
2020-01-01: #20333#20,33320202021-01-01: #13700#13,70020212022-01-07: #16596#16,59620222022-12-25: #15748#15,74820222023-07-30: #11770#11,77020232024-01-05: #8231#8,2312024

Rank in USA: #3,926 (Jan 2020) · #2,954 (Jan 2021) · #3,416 (Jan 2022) · #3,217 (Dec 2022) · #2,543 (Jul 2023) · #1,982 (Jan 2024)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
-192.3%
Operating margin
-193.7%
Return on equity
-32.2%
Liabilities / assets
37.4%

Annual results

Revenue
$30 M
Operating income
$-58 M
Net income
$-58 M

Dec-2022 ending year

Balance sheet

Total assets
$286 M
Total liabilities
$107 M
Total equity
$179 M

Dec-2022 ending year

Where Alpine Immune Sciences, Inc. operates: 1 country#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.

Present: offices, subsidiaries, branches or revenue (1 country)Nothing on fileDots mark countries too small to see. Hover, tap or tab to a country for its figures.

Only the headquarters country is on file for Alpine Immune Sciences, Inc.: no subsidiaries, branches, offices or country revenue elsewhere in the GLEIF register, its SEC filings or Wikidata.

Alpine Immune Sciences, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Alpine Immune Sciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2017$17 MPrivate placement after listing$10 to $50 million3equitySEC
Jun 2016$10 MPrivate placement after listing$10 to $50 million3equitySEC
Jan 2015$1 MNo. 1Under $2 million1equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Alpine Immune Sciences, Inc. compares in Biotechnology

  • Revenue$30 M · higher than 54% of 647
  • Net margin-192.3% · higher than 29% of 408

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Alpine Immune Sciences, Inc.🇺🇸$1.1 B—-192.3%—
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
Dec-2022 ending year
Balance sheet:
Dec-2022 ending year
Profile updated:
Nov 19, 2026

Figures from value.today research, Wikidata.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Alpine Immune Sciences, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Alpine Immune Sciences, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Alpine Immune Sciences, Inc.? Suggest a correction